Mixed Cryoglobulinaemia Vasculitis after Persistent Hepatitis C Virus Eradication
  • Margarida Gaudêncio
    Department of Internal Medicine, Hospital Distrital da Figueira da Foz, EPE, Figueira da Foz, Portugal
  • Rui Nogueira
    Department of Nephrology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
  • Nuno Afonso Oliveira
    Department of Nephrology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Faculty of Medicine, University of Coimbra, Coimbra, Portugal


Mixed cryoglobulinemia, hepatitis C virus, remission, vasculitis


Mixed cryoglobulinaemia vasculitis (MCV) is a systemic vasculitis of the small and medium-size vessels caused by active hepatitis C (HCV) infection in >80% of cases. Beuthien et al. presented the first case of MCV with undetectable HCV after 10 months of therapy. In the last few years, more authors have described other cases of symptomatic MCV after 1 year of persistent HCV eradication. Here, we present a case report of a 57-year-old man who developed MCV with renal involvement after 3 years of HCV eradication with interferon therapy.



  • Roccatello D, Saadoun D, Ramos-Casals M, Tzioufas AG, Fervenza FC, Cacoub P, et al. Cryoglobulinaemia. Nat Rev Dis Primers 2018;4(1):11.
  • Lauer G, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345(1):41–52.
  • Pol S, Parlati L, Jadoul M. Hepatitis C virus and the kidney. Nat Rev Nephrol 2019;15:73–86.
  • Dammaco F, Sansonno D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med 2013;369:1035–1045.
  • Boonyapisit K, Katiriji B. Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review. Muscle Nerve 2002;25(6):909–913.
  • Beauthien W, Mellinghoff H-U, von Kempis J. Vasculitic complications of interferon-alpha treatment for chronic hepatitis C infection: case report and review of literature. Clin Rheumatol 2005;24(5):507–515.
  • Kartha V, Franco L, Coventry S, McLeish K, Caster DJ, Schadt CR. Hepatitis C mixed cryoglobulinemia with undetectable viral load: a case series. JAAD Case Rep 2018;4:684–687.
  • Quartuccio L, De Marchi G, Fabris M, De Vita S. Development of type II cryoglobulinaemic syndrome after effective and persistent hepatitis C virus eradication. Rheumatology 2007;46(2):367–368.
  • Silva RF, Malvar B, Santos R, Pessegueiro P, Aniceto J, Ramalho V, et al. New onset of mixed cryoglobulinemia vasculitis after persistent hepatitis C virus eradication. Port J Nephrol Hypert 2013;27(4):289–294.
  • De Re V, Sansonno D, Simula MP, Caggiari L, Gasparotto D, Fabris M, et al. HCV-NS3 and IgG-Fc crossreative IgM in patients with type II mixed cryoglobulinemia and B-cell clonal proliferation. Leukemia 2006;20(6):1145–1154.
  • Rosa D, Saletti G, De Gregorio E, Zorat F, Comar C, D'Oro U, et al. Activation of naive B lymphocytes via CD81, a pathogenic mechanism for hepatitis C virus associated B lymphocyte disorders. Proc Natl Acad Sci USA 2005;102(51):18544–18549.
  • Views: 478
    HTML downloads: 73
    PDF downloads: 280

    Published: 2021-08-31
    Issue: 2021: Vol 8 No 8 (view)

    How to cite:
    Gaudêncio M, Rui Nogueira, Nuno Afonso Oliveira. Mixed Cryoglobulinaemia Vasculitis after Persistent Hepatitis C Virus Eradication. EJCRIM 2021;8 doi:10.12890/2021_002808.

    Most read articles by the same author(s)